Navigation Links
Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer

For patients with high-risk breast cancer treated with radical mastectomy and adjuvant chemotherapy, the addition of radiation therapy leads to better survival outcomes with few long-term toxic effects, according to a 20-year follow-up of a randomized trial, which appears in the January 19 issue of the Journal of the National Cancer Institute.

The British Columbia randomized radiation therapy trial was designed to determine the effect on survival of the addition of locoregional radiation therapy (radiation to the lymph nodes and chest wall) to a course of chemotherapy after radical mastectomy in premenopausal women with lymph node–positive breast cancer. Between 1979 and 1986, 318 patients were randomly assigned to receive no radiation therapy or to receive radiation. A 15-year follow-up found that radiation therapy was associated with improved breast cancer survival but not with overall survival.

In this 20-year follow-up of the British Columbia trial, Joseph Ragaz, M.D., of McGill University Health Center in Montreal, and colleagues found that the chemotherapy and radiation regimen, compared with chemotherapy alone, was associated with improvement in all end points analyzed. This included a 32% reduction in breast cancer mortality and a 27% reduction in overall mortality compared with chemotherapy alone. In addition, long-term toxic effects, including cardiac deaths, were acceptable for both groups of patients.

"Our results, and those from other groups, confirm that in situations where residual disease remains, adjuvant chemotherapy alone in high-risk breast cancer patients is suboptimal and that the addition of locoregional radiation therapy is important to achieve the highest cure rate," the authors write.

In an editorial, Timothy Whelan, B.M., B.Ch., and Mark Levine, M.D., of the Juravinski Cancer Centre in Hamilton, Ontario, discuss the use of locoregional radiation therapy in breast cancer patients and note that fewer clinicians accept its use in moderate-risk patients. "Because uncertainties continue about the effectiveness of locoregional radiation therapy after mastectomy in moderate-risk patients, we strongly urge that a randomized controlled trial be mounted to resolve these uncertainties," they write.


'"/>

Source:Journal of the National Cancer Institute


Related biology news :

1. Adding radiation decreases breast cancer recurrence
2. Duke Experiments Boost Radiations Cancer-Killing Effects
3. Radiation-killed bacteria vaccine induces broad immune response in mice
4. Radiation-armed robot rapidly destroys human lung tumors
5. Radiation after surgery doubles survival time for some lung cancer patients
6. Radiation therapy combo cures prostate cancer long-term
7. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
8. Gene Therapy For Parkinsons Disease Moves Forward In Animals
9. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
10. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
11. Discovery Promises Simpler Therapy for Sickle Cell Disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/15/2016)... , March 15, 2016 ... report published by Transparency Market Research "Digital Door Lock Systems ... Forecast 2015 - 2023," the global digital door lock systems ... Mn in 2014 and is forecast to grow at a ... of micro, small and medium enterprises (MSMEs) across the world ...
(Date:3/11/2016)... HANOVER, Germany , March 11, 2016 ... - Cross reference: Picture is available at AP Images ( ... scanner from DERMALOG will be used to produce the new refugee ... of other biometric innovations, at CeBIT in Hanover ... LF10 scanner from DERMALOG will be used to produce the new ...
(Date:3/9/2016)... -- This BCC Research report provides an overview of ... (RNA Seq) market for the years 2015, 2016 and ... data analysis, and services. Use this report ... such as RNA-Sequencing tools and reagents, RNA-Sequencing data analysis, ... segment and forecast their market growth, future trends and ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... , ... May 04, 2016 , ... ... no further than LaJollaCooks4u, San Diego’s premiere hands-on cooking experience. Offering everything from ... give mom an experience she won’t forget. , Guests that visit LaJollaCooks4u share ...
(Date:5/4/2016)... May 4, 2016  Bayer today announced that ... Stivarga ® (regorafenib) tablets for the treatment ... met its primary endpoint of a statistically significant ... evaluated the efficacy and safety of regorafenib in ... treatment with sorafenib. The safety and tolerability were ...
(Date:5/4/2016)... May 4, 2016 According to ... "Metabolomics Market - Global Industry Analysis, Size, Share, Growth, ... is anticipated to expand at a CAGR of 17.1% ... by 2024. Metabolomics is the extensive study ... biofluids, tissues or organisms. Together, these small molecules and ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nutrafol®, a first-to-market ... treat hormonal and stress related hair loss. With patent-pending formulas for both female ... opinion leaders in the medical and salon channels nationwide. , Dermatologists, Plastic ...
Breaking Biology Technology: